A Randomized, Double-blind, Placebo-controlled, Parallel Group, 2-part Study Investigating the Effect of LIK066 on Body Weight in Dysglycemic (Prediabetes or Type 2 Diabetes) and Normoglycemic Patients With Elevated Body Mass Index
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs LIK 066 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 12 Apr 2016 Status changed from recruiting to completed.
- 22 Feb 2016 Treatment arms changed from 3 to 6 as reported by ClinicalTrials.gov record.
- 22 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.